Bepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challenge

Annals of Allergy, Asthma and Immunology

Volumn 105, Issue 1, 2010, Pages 57-64

  Torkildsen, Gail L ^a   Williams, Jon I ^b   Gow, James A ^b   Gomes, Paul J ^c   Abelson, Mark B ^c,d,e   McNamara, Timothy R ^b  

^a Andover Eye Associates   (United States)

^b ISTA Pharmaceuticals Inc   (United States)

^c Ora Inc   (United States)

^d SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETOTASTINE; PLACEBO;

ADOLESCENT; ADULT; AGED; ALLERGIC CONJUNCTIVITIS; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EAR PRURITUS; EYE IRRITATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NASAL PRURITUS; NOSE CONGESTION; PALATE PRURITUS; PRIORITY JOURNAL; PROVOCATION TEST; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SCHOOL CHILD; SCORING SYSTEM; TASTE DISORDER; UNSPECIFIED SIDE EFFECT;

ADULT; ALLERGENS; CONJUNCTIVITIS, ALLERGIC; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE ANTAGONISTS; HUMANS; IMMUNIZATION; MALE; MIDDLE AGED; NASAL OBSTRUCTION; OPHTHALMIC SOLUTIONS; PIPERIDINES; PYRIDINES;

EID: 77954217398     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/j.anai.2010.04.005     Document Type: Article

References (46)

1. J. Gradman, and O.D. Wolthers Allergic conjunctivitis in children with asthma, rhinitis and eczema in a secondary outpatient clinic Pediatr Allergy Immunol 17 2006 524 526
2. B.M. Prenner, and E. Schenkel Allergic rhinitis: treatment based on patient profiles Am J Med 119 2006 230 237
3. P. Kosrirukvongs, N. Visitsunthorn, P. Vichyanond, and C. Bunnag Allergic conjunctivitis Asian Pac J Allergy Immunol 19 2001 237 244
4. D.L. Spangler, M.B. Abelson, A. Ober, and P.J. Gomes Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models Clin Ther 25 2003 2245 2267
5. F.P. Paulsen, M. Foge, A.B. Thale, B.N. Tillmann, and R. Mentlein Animal model for the absorption of lipophilic substances from tear fluid by the epithelium of the nasolacrimal ducts Invest Ophthalmol Vis Sci 43 2002 3137 3143
6. H.J. Crampton Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo-and active-controlled trial Clin Ther 25 2003 1975 1987
7. B.Q. Lanier, M.B. Abelson, and W.E. Berger Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge Clin Ther 24 2002 1161 1174
8. N. Mygind, L.P. Nielsen, and H.J. Hoffmann Mode of action of intranasal corticosteroids J Allergy Clin Immunol 108 suppl 1 2001 S16 S25
9. A.S. Bacon, P. Ahluwalia, and A.M. Irani Tear and conjunctival changes during the allergen-induced early-and late-phase responses J Allergy Clin Immunol 106 2000 948 954
10. E.W. Gelfand Inflammatory mediators in allergic rhinitis J Allergy Clin Immunol 114 suppl 5 2004 S135 S138
11. J. Bousquet, P. Chanez, and J.Y. Lacoste Eosinophilic inflammation in asthma N Engl J Med 323 1990 1033 1039
12. M.B. Abelson, L. Smith, and M. Chapin Ocular allergic disease: mechanisms, disease sub-types, treatment Ocul Surf 1 2003 38 60
13. I. Hansen, L. Klimek, R. Mosges, and K. Hormann Mediators of inflammation in the early and the late phase of allergic rhinitis Curr Opin Allergy Clin Immunol 4 2004 159 163
14. D.P. Skoner Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis J Allergy Clin Immunol 108 suppl 1 2001 S2 S8
15. M.B. Abelson, and D.L. Welch An evaluation of onset and duration of action of patanol (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model Acta Ophthalmol Scand Suppl 230 2000 60 63
16. M.B. Abelson, and A.P. Kaplan A randomized, double-blind, placebo-controlled comparison of emedastine 0.05% ophthalmic solution with loratadine 10 mg and their combination in the human conjunctival allergen challenge model Clin Ther 24 2002 445 456
17. M. Kato, A. Nishida, and Y. Aga Pharmacokinetic and pharmacodynamic evaluation of the central effect of the novel antiallergic agent bepotastine besilate Arzneimittelforschung 47 1997 1116 1124
18. S. Baba, T. Takasaka, and K. Baba Long-term treatment of TAU-284 (betotatine besilate) on perennial allergic rhinitis [in Japanese] J Clin Ther Med 13 1997 1361 1382
19. Y. Ishibashi, S. Harada, and M. Niimura Long-term treatment of TAU-284 (betotastine besilate) on chronic urticaria [in Japanese] J Clin Ther Med 13 1997 1337 1359
20. N. Yato, T. Murata, and N. Saito Anti-allergic activity of betotastine besilate (TAU-284), a new anti-allergic drug [in Japanese] Nippon Yakurigaku Zasshi 110 1997 19 29
21. A. Sakai, M. Kikuchi, N. Yato, H. Kikkawa, N. Saito, and H. Narita Inhibitory effect of betotastine besilate on antigen-induced airway eosinophil infiltration and peripheral blood eosinophilia in mice Arzneimittelforschung 47 1997 954 958
22. M. Ueno, N. Inagaki, H. Nagai, and A. Koda Antiallergic action of betotastine besilate (TAU-284) in animal models: a comparison with ketotifen Pharmacology 57 1998 206 214
23. Y. Ohashi Immunological study of a second-generation antihistamine: the effects of bepotastine besilate on cytokine production from the peripheral blood mononuclear cells in cedar pollen allergy patients [in Japanese] Prog Med 24 2004 157 159
24. O. Kaminuma, K. Ogawa, H. Kikkawa, M. Kikuchi, K. Naito, and K. Ikezawa A novel anti-allergic drug, betotastine besilate, suppresses interleukin-5 production by human peripheral blood mononuclear cells Biol Pharm Bull 21 1998 411 413
25. Talion [package insert] 2008 Tanabe Seiyaku Co Ltd Osaka, Japan
26. ® tablets on pediatric allergic rhinitis [in Japanese] Rinsho Igaku 18 2002 1371 1387
27. M. Ito, K. Agaogi, and H. Shimizu A clinical study of anti-allergy drugs in relation to allergic rhinitis [in Japanese] Allergol Immunol 10 2003 88 97
28. ® in relation to nasal congestion in allergic rhinitis [in Japanese] Prog Med 24 2004 2037 2044
29. M.B. Abelson, W.A. Chambers, and L.M. Smith Conjunctival allergen challenge: a clinical approach to studying allergic conjunctivitis Arch Ophthalmol 108 1990 84 88
30. M.B. Abelson, and O. Loeffler Conjunctival allergen challenge: models in the investigation of ocular allergy Curr Allergy Asthma Rep 3 2003 363 368
31. M.B. Abelson Comparison of the conjunctival allergen challenge model with the environmental model of allergic conjunctivitis Acta Ophthalmol Scand Suppl 228 1999 38 42
32. L.J. Rosenwasser, M.B. Abelson, P.J. Gomes, and K. Kennedy A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis Allergy Asthma Proc 29 2008 644 653
33. H.J. Crampton A comparison of the relative clinical efficacy of a single dose of ketotifen fumarate 0.025% ophthalmic solution versus placebo in inhibiting the signs and symptoms of allergic rhinoconjunctivitis as induced by the conjunctival allergen challenge model Clin Ther 24 2002 1800 1808
34. M.B. Abelson, P.J. Gomes, and C.T. Vogelson Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis Curr Med Res Opin 21 2005 683 691
35. M.B. Abelson Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model Ann Allergy Asthma Immunol 81 1998 211 218
36. M.B. Abelson, M.J. Chapin, B.M. Kapik, and N.B. Shams Efficacy of ketotifen fumarate 0.025% ophthalmic solution compared with placebo in the conjunctival allergen challenge model Arch Ophthalmol 121 2003 626 630
37. M.B. Abelson, P. Gomes, H.J. Crampton, R.M. Schiffman, R.R. Bradford, and S.M. Whitcup Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis Clin Ther 26 2004 35 47
38. M.B. Abelson, and D. Turner A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis Clin Ther 25 2003 931 947
39. M.B. Abelson, G.L. Torkildsen, and J.I. Williams Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children Clin Ther 31 2009 1908 1921
40. M.B. Abelson, and L. Spitalny Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity Am J Ophthalmol 125 1998 797 804
41. D.S. Moore, and G.P. McCabe Comparing two proportions Introduction to the Practice of Statistics 1993 WH Freeman & Co New York, NY 590 596
42. W. Berger, F. Hampel, and J. Bernstein Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis Ann Allergy Asthma Immunol 97 2006 375 381
43. K. Ukai, M. Takeuchi, and S. Masuda Clinical pharmacological study of antiallergic agent TAU-184 (bepotastine besilate): the effect on counting of eosinophils in nasal discharge, and the patency improvement of nasal cavity [in Japanese] J Clin Ther Med 13 1997 1401 1412
44. K. Hashiguchi, H. Tang, and T. Fujita Bepotastine besilate OD tablets suppress nasal symptoms caused by Japanese cedar pollen exposure in an artificial exposure chamber (OHIO Chamber) Expert Opin Pharmacother 10 2009 523 529
45. G.W. Ousler, K.A. Wilcox, G. Gupta, and M.B. Abelson An evaluation of the ocular drying effects of 2 systemic antihistamines: loratadine and cetirizine hydrochloride Ann Allergy Asthma Immunol 93 2004 460 464
46. D. Welch, G.W. Ousler III, L.A. Nally, M.B. Abelson, and K.A. Wilcox Ocular drying associated with oral antihistamines (loratadine) in the normal population: an evaluation of exaggerated dose effect Adv Exp Med Biol 506 2002 1051 1055